{
    "id": "dbpedia_7928_2",
    "rank": 26,
    "data": {
        "url": "https://www.linkedin.com/posts/davidshapironyc_i-have-to-jump-on-the-bandwagon-here-and-activity-7088207087037501440-lxm1",
        "read_more_link": "",
        "language": "en",
        "title": "David Shapiro on LinkedIn: I have to \"jump on the bandwagon\" here and add my rave review of this…",
        "top_image": "https://media.licdn.com/dms/image/D4E22AQGc9FSKZ-hhFQ/feedshare-shrink_800/0/1689941247856?e=2147483647&v=beta&t=Ga4aYTsV5OHrd5u4SHTnquqnJHD7wXi2EcUBPSQCCQ8",
        "meta_img": "https://media.licdn.com/dms/image/D4E22AQGc9FSKZ-hhFQ/feedshare-shrink_800/0/1689941247856?e=2147483647&v=beta&t=Ga4aYTsV5OHrd5u4SHTnquqnJHD7wXi2EcUBPSQCCQ8",
        "images": [
            "https://media.licdn.com/dms/image/v2/D5616AQESd9MASbNyEQ/profile-displaybackgroundimage-shrink_200_800/profile-displaybackgroundimage-shrink_200_800/0/1713303268354?e=2147483647&v=beta&t=eWiL__qHcrFAUTACLwn6MmuYQtRfFsY2yQ6L8C30rgk"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "David Shapiro"
        ],
        "publish_date": "2023-07-21T17:24:22.050000+00:00",
        "summary": "",
        "meta_description": "I have to &quot;jump on the bandwagon&quot; here and add my rave review of this event. This was one of the best networking events I have *ever* attended. I saw…",
        "meta_lang": "en",
        "meta_favicon": "https://static.licdn.com/aero-v1/sc/h/al2o9zrvru7aqj8e1x2rzsrca",
        "meta_site_name": "",
        "canonical_link": "https://www.linkedin.com/posts/davidshapironyc_i-have-to-jump-on-the-bandwagon-here-and-activity-7088207087037501440-lxm1",
        "text": "A B2i Digital Featured Company AIM ImmunoTech (NYSE American: $AIM) https://lnkd.in/erRzxGa9 reported Q2 2024 financial results and provided a corporate update today. Highlights from the quarter include: - Publication in the peer-reviewed journal Vaccines of new positive data on Ampligen’s anti-tumor potential when used as part of a combination therapy for the treatment of melanoma. - AIM reported $10.1 million in cash, cash equivalents, and marketable securities as of June 30, 2024. - Continued execution across Ampligen clinical development programs and a growing body of positive data in multiple high-value indications. - The release of several CEO Corner segments highlighting Company news and programs. AIM CEO Thomas K. Equels commented, “We continue to see great potential in Ampligen as we progress across our clinical development programs and look forward to results from our ongoing studies in the near future. Our entire team remains dedicated to patients and stockholders and will continue to drive momentum across our operational, clinical and regulatory initiatives throughout the remainder of 2024. We strongly believe in the potential of Ampligen to have a meaningful therapeutic benefit across multiple indications as well as the opportunity to unlock significant shareholder value.” View the second quarter results at this link: https://lnkd.in/eT-zXKjM AIM’s management team includes CEO Tom Equels, COO Peter Rodino III, CMO David Strayer, Scientific Officer Chris McAleer PhD, and CFO Robert Dickey. We commend the company’s continued progress in advancing Ampligen and its dedication to developing therapies to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. For Investor Relations questions, please contact Jenene Thomas and her team at JTC IR and sign up to receive news email alerts from AIM, including the CEO Corner Series, at https://lnkd.in/e6grvEvX. #Biotech #ClinicalTrials #Ampligen #B2iDigital #AIMImmunoTech #ImmunoOncology #Melanoma #immunotherapy #Q22024\n\nA B2i Digital Featured Company, Unicycive Therapeutics (Nasdaq: $UNCY) https://lnkd.in/eg9U-h4f, announced financial results for Q2 2024 and provided a business update. Among the highlights in the company’s news release were: - Unicycive is on track to submit OLC New Drug Application (NDA) by the end of August 2024 - Pivotal trial confirmed OLC tolerability in patients with hyperphosphatemia on dialysis. There were no treatment-related serious adverse events (SAEs). - The Company believes it has completed all requirements from the pivotal clinical trial to fulfill the FDA’s requests. - Granted new patent for UNI-494 by USPTO, valid until 2040 - The patent secures protection for treating acute kidney injury or contrast-induced nephropathy using UNI-494. - Cash position of $41.8 million as of June 30, 2024, which the Company believes is sufficient to fund planned operations into 2026 - Included in the Russell Microcap Index effective July 1, 2024 CEO and Founder Dr. Shalabh Gupta, MD stated, “Achieving successful results from our oxylanthanum carbonate (OLC) pivotal trial was a significant milestone for the company and brings us one step closer to becoming a commercial organization. Importantly, the trial confirmed tolerability of OLC in patients with hyperphosphatemia on dialysis which is the final data component needed to support submission of a New Drug Application (NDA) to the FDA utilizing the 505(b)(2) regulatory pathway.” He also noted, “With assets targeting both chronic and acute kidney conditions, we remain steadfastly focused on improving treatment options and overall quality of life for patients living with renal diseases.” Please click the link to see the full financial results and business update: https://lnkd.in/g_uXSz53 B2i Digital commends Dr. Gupta and his management team, including John Townsend, Doug Jermasek, EVP Pramod Gupta, Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, on their continued progress in addressing unmet needs in kidney disease treatment. Please visit Unicycive’s https://unicycive.com/ and B2i Digital’s https://b2idigital.com/ websites to learn more. #biotech #medtech #kidneydisease #innovation #clinicaltrials #B2iDigital #Unicycive #OLC #UNCY #UNI494 #Q2Earnings #BusinessUpdate DISCLAIMER: B2i Digital’s CEO, David Shapiro, owns 46,000 shares of unrestricted UNCY stock as of August 14, 2024. This post is not intended to solicit the sale of UNCY or any security, and it is not intended to offer any opinion on UNCY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclaimer in the Risks and Disclosures section of https://lnkd.in/eg9U-h4f.\n\nA B2i Digital Featured Company, Kolibri Global Energy Inc. (Nasdaq: KGEI, TSX: KEI), https://lnkd.in/eVHcxRGp, released its second quarter 2024 financial and operating results, which featured a 30% production increase and a 38% revenue increase. Wolf Regener, President and CEO, commented: “We are pleased that the Company continues to increase production and Adjusted EBITDA as we demonstrate the growth potential of the Tishomingo field. Average production increased by 30% and Adjusted EBITDA increased 31% in the second quarter of 2024 compared to the second quarter of 2023 demonstrating our continued growth. We are excited to enter into a new phase of the Company’s development where we believe the most economic and efficient strategy is to drill longer laterals. We just started drilling the three Alicia Renee wells (all 100% working interest) that will each have a 1.5 mile lateral and we expect to bring those wells on production early in the fourth quarter of 2024.” Highlights from the Q2 2024 results include: - Average production increased 30% to 3,128 BOEPD compared to Q2 2023 - Revenue, net of royalties, increased 38% to $13.9 million compared to Q2 2023 - Adjusted EBITDA increased 31% to $10.0 million compared to Q2 2023 - Net income was $4.1 million with EPS of $0.11/share - As of June 30, 2024, the Company had $16 million of available borrowing capacity on its credit agreement For the full earnings release, please visit: https://lnkd.in/eTcrrfzT Kolibri focuses on acquiring and developing energy projects across the United States. The company’s success is driven by an experienced management team, including Gary Johnson, CPA, MBA, CFO, Allan Hemmy, Senior Geologist, and Dalia \"Lupita\" Isaac, Landman, who provide substantial industry expertise to drive continued growth and development. Kolibri has established a shareholder loyalty program in partnership with B2i Digital and TiiCKER. Current and prospective shareholders can learn more at https://lnkd.in/eW89Uiv2. #KolibriGlobalEnergy #EnergySector #OilProduction #Q22024Results #ShareholderReturns #B2iDigital #KGEI #KEI #ShareholderLoyalty #TiiCKER #ShareholderPerks #EnergyInnovation\n\nA B2i Digital Featured Company, Sonim Technologies, Inc. (Nasdaq: $SONM) https://lnkd.in/eXCbcv4h reported financial results for the second quarter ended June 30, 2024, and provided updates on its strategic initiatives. According to the release, Sonim has begun commercial launches from its expanding portfolio of new rugged mobile and connected solutions devices. The company indicated it expects sequential sales growth in the third and fourth quarters, driven by these new product introductions. Sonim's CEO, Peter Liu, stated, “We are excited to initiate the first commercial launches from our expanding portfolio of new rugged mobile and connected solutions devices. As a result of these new products and broad-based distribution, we expect sequential sales growth in both the third and fourth quarters. Our design awards with all tier-one carriers in the United States and Canada position us to significantly broaden our market reach. This expansion will elevate Sonim’s addressable market from a legacy market of approximately $400 million to a diverse global market valued at over $50 billion annually.” Highlights from the Q2 2024 results and recent developments include: - Commenced launches for two of the 14 new product awards Sonim has secured to date with carriers in North America, Europe, and Australia. - Secured a new product award for the 5G variant of the Sonim XP3plus flip phone with a tier-one carrier in the U.S. - Secured a new product award for a new mobile hotspot from the connected solutions portfolio with a tier-one carrier in the Nordics, scheduled to launch in the second half of 2024. - Gross profit increased to $3.0 million, or 26% of revenues, compared with the first quarter of 2024 gross profit of $2.9 million, or 17% of revenues, due to the discontinuation of lower-margin white-label products. - Sonim ended the quarter with $9.6 million in cash and equivalents, remaining essentially debt-free. Please see the full release: https://lnkd.in/e6HRMVhm B2i Digital commends Sonim’s leadership, including CEO Peter Liu, CFO Clay Crolius, CPA, Chief Commercial Officer Charles (Chuck) Becher, SVP Chris Yeatts, and VP of Global Marketing Anette Gaven, as well as the entire Sonim team for their strategic initiatives and expansion into new product categories and markets. Contact Sonim’s IR firm, Darrow Associates, including Matthew Kreps, at mkreps@darrowir.com and his team with any questions, and visit https://b2idigital.com regularly for the latest updates on Sonim’s progress. #B2iDigital #SonimTechnologies #Q22024Results #RuggedMobile #ConnectedSolutions #GlobalExpansion\n\nA B2i Digital Featured Company, Beneficient (Nasdaq: $BENF) https://lnkd.in/ehVZg6fM, a technology-enabled financial services holding company that provides liquidity, primary capital, and related trust and custody services to holders of alternative assets, announced that the Company entered into a securities purchase agreement with YA II PN, LTD (“Yorkville”). According to the news release, the agreement includes the issuance of convertible debentures in an aggregate principal amount of up to $4,000,000 and warrants to purchase up to 1,325,382 shares of the Company’s Class A common stock at an exercise price of $2.63. Upon signing the agreement, the Company issued $2,000,000 in aggregate principal amount of Convertible Debentures and Warrants to purchase up to 662,691 shares of Common Stock. The Company states it intends to use proceeds from the transaction for general corporate purposes. For more details, please see Beneficient’s full press release: https://lnkd.in/ejBzSVja B2i Digital is pleased to recognize Beneficient’s skilled leadership team, including CEO and Chairman Brad Heppner, President & Chief Fiduciary Officer Derek Fletcher, Global Head of Originations & Distribution Jeff Welday, CIMA, CFO Greg Ezell, Chief Underwriting Officer Scott Wilson, General Counsel David Rost, CTO Maria Rutledge, VP Marketing Shileen Weber, CDMP, and IR Dan Callahan. If you have questions about today’s news release, contact Michael Wetherington and Matthew Kreps from Beneficient’s IR firm, Darrow Associates.For more news, updates, and information about Beneficient, please visit B2i Digital https://b2idigital.com/. #B2iDigital #Beneficient #AlternativeAssetLiquidity #FinTech #GPsolutions #Innovation #Growth #BENF"
    }
}